Mall PA
CJC-1295 NOT FOR HUMANS BANNED IN TESTED SPORT
File 07 · synthetic analog of growth hormone-releasing hormone (GHRH)

CJC-1295

Also called: CJC-1295 with DAC (drug affinity complex), CJC-1295 without DAC / no DAC, modified GRF (1-29), Mod GRF 1-29

Banned · S2Very limited

CJC-1295 is a modified version of the first 29 amino acids of GHRH, the hormone that signals the pituitary to release growth hormone. The 'DAC' version carries a chemical linker that binds the peptide to albumin in the blood, stretching its half-life from minutes to days; 'no DAC' (often sold as Mod GRF 1-29) is short-acting.

Why the gym talks about it

It is marketed as a way to raise natural growth hormone and IGF-1 for recovery, sleep and body composition, and is commonly paired with ipamorelin.

What the research actually found

  • small human trial (pharmacology)In healthy adults, a single injection of CJC-1295 with DAC raised average GH 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9-11 days; its half-life was about 6-8 days. Source
  • small human trial (pharmacology)GH continued to be released in pulses during continuous stimulation by CJC-1295, with higher trough levels. Source
  • human trial (halted)A phase 2 trial for HIV-related abdominal fat was halted in July 2006 after a participant died; the cause and any link to the drug were under investigation at the time, and the drug was not developed further. Source

Human evidence: very limited. Only short pharmacology studies in healthy adults show it raises GH and IGF-1; there are no outcome trials for muscle, fat loss or recovery, and clinical development stopped.

Tested lifters

S2.2.4 GHRH and its analogues. CJC-1295 is named; prohibited at all times.

High. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.

FDA status

Not FDA-approved. CJC-1295 is not on FDA's interim 503A categories list (May 14, 2026 version), so it is not eligible for 503A compounding. FDA's safety-risk page cites serious adverse events including increased heart rate and a systemic vasodilatory reaction.

As of 2026-10-01.

Known and theoretical risks

  • FDA cites serious adverse events including increased heart rate and a systemic vasodilatory reaction. Source
  • The DAC version keeps GH and IGF-1 raised for more than a week after a single exposure, and effects accumulate with repeated exposure. Source
  • A trial participant died in 2006, with causality never publicly established. Source

Quick answers

Is CJC-1295 banned for drug-tested lifters?

S2.2.4 GHRH and its analogues. CJC-1295 is named; prohibited at all times. High. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.

Is CJC-1295 FDA approved?

Not FDA-approved. CJC-1295 is not on FDA's interim 503A categories list (May 14, 2026 version), so it is not eligible for 503A compounding. FDA's safety-risk page cites serious adverse events including increased heart rate and a systemic vasodilatory reaction.

How strong is the human evidence for CJC-1295?

Very limited. Only short pharmacology studies in healthy adults show it raises GH and IGF-1; there are no outcome trials for muscle, fat loss or recovery, and clinical development stopped.

Sources

Research-use-only information file. Nothing here is medical advice or instructions for use. Not evaluated by the FDA. Talk to your doctor.

More files

Back to the basement